Marksans Pharma Ltd. - Research Center

---

Results

• Quarterly
• Half yearly
• Annual

Statement

• Balance sheet
• P&L
• Cash flow

More

• Dividend
• Share holding
• Capital structures
• Ratio

Mar ' 23	Mar ' 22	Mar ' 21	Mar ' 20	Mar ' 19

Sales

655.20

658.29

599.55

433.42

424.16

Operating profit

91.90

113.72

113.71

71.49

63.33

Interest

3.61

3.80

5.35

7.29

6.56

Gross profit

148.77

152.17

139.52

64.37

64.70

EPS (Rs)

2.27

2.54

2.40

0.93

1.07

Other income

60.48

42.25

31.16

0.17

7.93

Stock adjustment

-10.19

3.89

0.55

-5.63

-2.71

Raw material

338.49

327.99

291.29

209.20

208.14

Power and fuel

-

-

-

-

-

Employee expenses

56.09

60.46

54.64

48.51

46.33

Excise

-

-

-

-

-

Admin and selling expenses

-

-

-

-

-

Research and development expenses

-

-

-

-

-

Expenses capitalised

-

-

-

-

-

Other expenses

178.91

152.23

139.35

109.85

109.07

Provisions made

-

-

-

-

-

Depreciation

16.74

17.66

15.19

11.64

8.69

Taxation

29.17

30.52

25.95

14.82

12.39

Net profit / loss

102.87

103.99

98.38

37.90

43.62

Extra ordinary item

-

-

-

-

-

Prior year adjustments

-

-

-

-

-

Equity capital

45.32

40.93

40.93

40.93

40.93

Equity dividend rate

-

-

-

-

-

Agg.of non-prom. shares (Lacs)

-

-

-

-

-

Agg.of non promotoholding (%)

-

-

-

-

-

OPM (%)

14.03

17.27

18.97

16.49

14.93

GPM (%)

20.79

21.72

22.12

14.85

14.97

NPM (%)

14.37

14.84

15.60

8.74

10.09